Product Description: HX531 is an effective RXR antagonist with oral activity, with an IC50 of 18 nM, with activity against black melanoma. HC531 can eliminate the anti-apoptotic effects of all-trans-retinoic acid (t-RA) and exerts anti-obesity and anti-diabetic effects through leptin-dependent pathways and the p53-p21Cip1 pathway, resulting in G0/G1 cell cycle arrest[1][2][3].
Applications: Metabolism-sugar/lipid metabolism
Formula: C29H29N3O4
References: [1]Konta T, et al. Selective roles of retinoic acid receptor and retinoid x receptor in the suppression of apoptosis by all-trans-retinoic acid. J Biol Chem. 2001 Apr 20;276(16):12697-701. /[2]Yamauchi T, et al. Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest. 2001 Oct;108(7):1001-13./[3]Atsuko Nakatsuka, et al. RXR antagonism induces G0 /G1 cell cycle arrest and ameliorates obesity by up-regulating the p53-p21(Cip1) pathway in adipocytes. J Pathol. 2012 Apr;226(5):784-95./[4]Wenrui Zhao, et al. RXR signaling targeted cancer therapy. January 2023The Innovation Life 1(1):100014
CAS Number: 188844-34-0
Molecular Weight: 483.56
Compound Purity: 99.87
Research Area: Cancer; Metabolic Disease
Solubility: DMSO : 33.33 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Apoptosis;RAR/RXR
Deutsch
English
